Navigation Links
Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
Date:2/17/2012

SAINT PAUL, Minn., Feb. 17, 2012 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today scheduled a conference call to discuss its financial results for the first quarter fiscal 2012, ended January 31, 2012. The call will be at 5:00 p.m. ET on Tuesday, February 28, 2012. The Company will report financial results for the first quarter fiscal 2012 at the close of the market on Tuesday, February 28, 2012.

Those wishing to participate can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at www.angeion.com. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10010101, through March 5, 2012. A webcast replay of the conference call will be accessible on the Company's website at www.angeion.com for 90 days.

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

 Contact: Robert M. Wolf

Joe Dorame, Robert Blum, Joe Diaz  

Angeion Corporation

Lytham Partners, LLC 

Chief Financial Officer

(602) 889-9700 

(651) 484-4874

angn@lythampartners.com 


'/>"/>
SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
3. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
4. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. CEL-SCI Corporation Releases Letter to Shareholders
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
Breaking Medicine Technology:
(Date:12/11/2016)... PA (PRWEB) , ... December 11, 2016 , ... It’s ... nasal allergies that flare up. Tired of the sneezing, watery eyes and general discomfort ... solve this problem. , He then created a prototype of the patent-pending CLEAN AIR ...
(Date:12/10/2016)... ... December 09, 2016 , ... Even with breast cancer cited ... in recent years. This can be attributed to the improvement in breast cancer ... distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast Cancer Care” spotlights the ...
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... ... presence in Harrisburg. PATS recently joined forces with other healthcare organizations to ... the State Capitol Rotunda in Harrisburg, featured a variety of speakers from around ...
(Date:12/9/2016)... MD (PRWEB) , ... December 09, 2016 , ... ... for counseling and aural rehabilitation—provided by audiologists—to remain a critical part of public ... Food and Drug Administration (FDA) announced this week that, starting immediately, ...
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
Breaking Medicine News(10 mins):